It’s great to be back home, even while the drama surrounding MMS continues to unfold. The FDA is, albeit unintentionally, calling more attention to MMS and itself by embarking on this latest smear campaign. It’s a smear campaign because due diligence has not been followed on the FDA’s part. This is becoming the rule, not the isolated exception. MMS is…
Read More
